Company profile

Viatris Inc

NASDAQ:VTRSBiotechnology: Pharmaceutical Preparations

Drug pipeline (315)

AssetStageRevenueTrialsStatus
ABACAVIRapproved0
Abacavir Sulfateapproved0
ABIRATERONE ACETATEapproved26approved
Acamprosate calciumapproved0
Acetaminophenapproved78approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (557)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00159757phase4terminated2003-11-01Pfizer's Upjohn has merged with Mylan to form Viatris Inc.12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT01061372phase3withdrawn2010-05-012011-08-01Pfizer's Upjohn has merged with Mylan to form Viatris Inc.12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
NCT00312494phase3completed2006-04-012008-12-01Pfizer's Upjohn has merged with Mylan to form Viatris Inc.3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
NCT00739999phase1completed2008-12-012009-05-01Pfizer's Upjohn has merged with Mylan to form Viatris Inc.8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
NCT01463306phase3completed2012-02-212019-08-22Pfizer's Upjohn has merged with Mylan to form Viatris Inc.A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

FDA applications (483)

ApplicationTypeApplicantProducts
ANDA 018659ANDAMYLAN PHARMACEUTICALS INC
ANDA 020167ANDAMYLAN PHARMS INC
ANDA 040209ANDAMYLAN PHARMACEUTICALS INC
ANDA 040298ANDAMYLAN PHARMACEUTICALS INC
ANDA 040350ANDAMYLAN PHARMACEUTICALS INC